Cilansetron hydrochloride anhydrous | 120635-72-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: Cilansetron hydrochloride anhydrous
• 英文别名: (12R)-12-[(2-methylimidazol-1-yl)methyl]-1-azatetracyclo[7.6.1.05,16.010,15]hexadeca-5(16),6,8,10(15)-tetraen-11-one;hydrochloride
• CAS: 120635-72-5
• 化学式: C20H22ClN3O
• 分子量: 355.9
• InChiKey: PGMSXNFJFNKUGN-XFULWGLBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.96
• 重原子数：
  25
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  39.8
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Medicament containing cilansetron for the treatment of non-obstipative male irritable bowel syndrome patients
  申请人：——

  公开号：US20020040033A1

  公开（公告）日：2002-04-04

  The present invention relates to the use of cilansetron for the treatment of non-obstipative male IBS patients.

  本发明涉及使用西兰司琼治疗非便秘性男性肠易激综合征患者。
• Method of treating or inhibiting a non-digestive tract derived abdominal disorder associated with pain using a 5-HT, receptor antagonist
  申请人：Sann Holger

  公开号：US20050209293A1

  公开（公告）日：2005-09-22

  A method of treating or inhibiting non-digestive tract derived abdominal disorders associated with pain, in particular interstitial cystitis, chronic pelvic pain syndrome and/or abdominal pain associated with endometriosis, in a patient in need thereof, by administering to the patient a pharmaceutically effective amount of a 5-HT 3 receptor antagonist, in particular cilansetron, or a pharmacologically compatible derivative thereof, such as a salt and/or a solvates.

  一种治疗或抑制与疼痛相关的非消化道衍生腹部疾病，特别是间质性膀胱炎、慢性盆腔疼痛综合征和/或与子宫内膜异位症相关的腹痛的方法，该方法通过向有需要的患者施用药学有效量的 5-HT 3 受体拮抗剂，特别是西兰司琼，或其药理相容的衍生物，如盐和/或溶物。
• "Gegen Racemisierung stabilisierte pharmazeutische Zubereitungen von Cilansetron"
  申请人：Solvay Pharmaceuticals GmbH

  公开号：EP0895782B1

  公开（公告）日：2004-12-01
• USE OF A 5-HT3 RECEPTOR ANTAGONIST FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF NON-DIGESTIVE TRACT DERIVED ABDOMINAL DISORDERS ASSOCIATED WITH PAIN
  申请人：Solvay Pharmaceuticals GmbH

  公开号：EP1727527A1

  公开（公告）日：2006-12-06
• METHOD OF SCREENING THERAPEUTIC AGENT FOR IRRITABLE BOWEL SYNDROME
  申请人：Astellas Pharma Inc.

  公开号：EP1857816B1

  公开（公告）日：2010-03-10